NeurAxis, Inc. (NRXS)
- Previous Close
2.2700 - Open
5.5700 - Bid 3.6200 x 1800
- Ask 3.6400 x 900
- Day's Range
3.5000 - 6.2000 - 52 Week Range
1.3300 - 6.2000 - Volume
83,926,453 - Avg. Volume
27,921 - Market Cap (intraday)
25.846M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.75
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
neuraxis.comRecent News: NRXS
View MorePerformance Overview: NRXS
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRXS
View MoreValuation Measures
Market Cap
16.38M
Enterprise Value
14.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.53
Price/Book (mrq)
64.44
Enterprise Value/Revenue
5.03
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-286.19%
Return on Assets (ttm)
-220.12%
Return on Equity (ttm)
--
Revenue (ttm)
2.93M
Net Income Avi to Common (ttm)
-8.82M
Diluted EPS (ttm)
-1.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
2.01M
Total Debt/Equity (mrq)
150.39%
Levered Free Cash Flow (ttm)
-4.49M